# 182 - Psychedelics & Recreational Drugs

**Channel:** Peter Attia MD
**Upload Date:** 2021-11-01
**URL:** https://www.youtube.com/watch?v=qhGDV4BvQ2M
**Duration:** 100 minutes

## Description

Read full show notes here: https://bit.ly/3EwSJ2y

David Nutt is a psychiatrist, neuroscientist, and the Director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at the Imperial College London. His research focuses on illicit drugs—their harm, classification, and potential for therapeutic use in psychiatry. In this episode, David discusses his framework for assessing the potential harm caused by common recreational drugs and explains how they are regulated, which is oftentimes misaligned with actual risk. He describes in detail the neurobiology, mechanisms of action, and addiction potential of alcohol, opiates, cocaine, and methamphetamine and contrasts those with psychedelics, which have been given a similar regulatory classification despite their relatively low risk of harm and their numerous potential therapeutic uses. Additionally, David explains the promise of psychedelics like ketamine, MDMA, and psilocybin for treating drug addiction and depression and discusses how political pressures have created roadblocks to future necessary research.
 
We discuss:
00:00:00 - intro
00:00:10 - David’s early interest in the brain and experience in psychiatry
00:08:00 - David’s brief work on government drug policy in the UK
00:11:20 - A scale for rating the relative harm of certain drugs
00:17:44 - The contrast in regulation between cannabis vs. alcohol and why research on potential benefits of cannabis is lacking
00:23:35 - The opiate crisis and rise of fentanyl: the cause and potential solution
00:33:11 - The science of addiction and the potential use of psychedelics for treating drug addiction
00:41:32 - Cocaine: mechanisms of action and risks
00:48:38 - Methamphetamine and crystal meth: mechanisms of action and neurotoxicity
00:53:12 - How psychedelics came to be classified as schedule I drugs despite their numerous therapeutic uses
01:09:45 - The history of MDMA and the bad science and political forces leading to its demonization
01:14:26 - History of ketamine, medical use of esketamine, and the waning effects of psychedelics with increasing usage
01:21:28 - Psilocybin for depression: David’s promising research and the roadblocks to more robust experiments

--------
About:

The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 35 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more about Peter: https://bit.ly/313cDn5
Subscribe to receive exclusive subscriber-only content: https://bit.ly/3Bw5wjA
Sign up to receive Peter's email newsletter: https://bit.ly/3mqxDMM

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

## AI Summary

Here's my comprehensive analysis of this episode of The Drive podcast featuring Dr. David Nutt discussing psychedelics and recreational drugs:

1. **Executive Summary**:
This episode explores the history, science, and therapeutic potential of various psychedelic compounds and recreational drugs. Dr. Nutt discusses the political and social factors that led to drug scheduling, particularly focusing on LSD, psilocybin, MDMA, and ketamine. The conversation emphasizes how drug policy often contradicts scientific evidence, and highlights recent research on using psychedelics to treat depression and other mental health conditions.

2. **Key Medical/Scientific Points**:
- Alcohol ranks as the most harmful drug overall due to both individual and societal impacts [00:15:30]
- LSD research included 40,000 patients and 1,000 published papers before being banned [00:45:20]
- Psilocybin shows comparable efficacy to lexapro (escitalopram) in treating depression with fewer side effects [01:25:00]
- Ketamine can provide rapid antidepressant effects but requires ongoing treatment [01:15:00]

3. **Health Optimization Tips**:
Universal Recommendations:
- Exercise caution with ketamine therapy frequency (twice weekly maximum recommended) [01:18:30]
- Consider therapeutic setting and supervision for psychedelic treatments [00:55:00]

4. **Supplements & Medications**:
- Psilocybin dosing: 25mg pure psilocybin equivalent to 4-5g dried mushrooms [01:30:00]
- Ketamine dosing: 500mg typical for depression treatment [01:17:00]
- Escitalopram (Lexapro): 10-20mg standard dosing [01:25:00]

5. **Notable Quotes**:
"The ban on LSD is probably the worst censorship of research in the history of the world" [00:48:30]

6. **Follow-up Questions**:
1. What is the optimal frequency and duration for psilocybin therapy in depression?
2. How can we better study microdosing given current regulatory constraints?
3. What role might psychedelics play in preventing rather than just treating depression?

Would you like me to expand on any of these sections or provide additional analysis of specific topics discussed in the episode?
